Accounting for TLD response to CBCT protocols in external beam radiotherapy dose monitoring
Journal of Applied Clinical Medical Physics, EarlyView.Abstract Purpose LiF thermoluminescent dosimeters (TLDs) are commonly used in radiation therapy to verify the delivered dose. Examples include dose verification for complicated treatment setups or cardiovascular implantable electronic devices (CIEDs). TLDs may be present for both the pre‐treatment imaging kilovoltage (kV) beam and the megavoltage (MV ...
Andrew J. White +5 more
wiley +1 more source
Variable selection for partially linear proportional hazards model with covariate measurement error. [PDF]
J Nonparametr Stat, 2019 Song X, Wang L, Ma S, Huang H.
europepmc +1 more source
A Gamma-frailty proportional hazards model for bivariate interval-censored data. [PDF]
Comput Stat Data Anal, 2018 Gamage PWW, McMahan CS, Wang L, Tu W.
europepmc +1 more source
Proportional hazards model with a change point for clustered event data. [PDF]
Biometrics, 2017 Deng Y, Zeng D, Zhao J, Cai J.
europepmc +1 more source
Tuning Parameter Selection in Cox Proportional Hazards Model with a Diverging Number of Parameters. [PDF]
Scand Stat Theory Appl, 2018 Ni A, Cai J.
europepmc +1 more source
Calcium modulating ligand confers risk for Parkinson's disease and impacts lysosomes
Annals of Clinical and Translational Neurology, EarlyView.Abstract Objective Several genetic loci known to confer risk for Parkinson's disease (PD) function in lysosomal pathways. We systematically screened common variants linked to PD risk by genome‐wide association studies (GWAS) for impact on cerebrospinal fluid (CSF) proteins reflecting lysosomal function.
Hanwen Zhang +16 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.Abstract Objectives An increasing body of evidence indicates altered DNA methylation in Parkinson's disease, yet the reproducibility and utility of such methylation changes are largely unexplored. We aimed to further elucidate the role of dysregulated DNA methylation in Parkinson's disease and to evaluate the biomarker potential of methylation‐based ...
Ingeborg Haugesag Lie +4 more
wiley +1 more source
Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD
Annals of Clinical and Translational Neurology, EarlyView.Abstract Objective Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid‐beta 42 (Aβ42) levels, may hold potential as predictive ...
Maria Camila Gonzalez +15 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.Abstract Objectives This study sought to evaluate proteomic, metabolomic, and immune signatures in the cerebrospinal fluid of individuals with Down Syndrome Regression Disorder (DSRD). Methods A prospective case–control study comparing proteomic, metabolomic, and immune profiles in individuals with DSRD was performed.
Jonathan D. Santoro +12 more
wiley +1 more source
Liraglutide for idiopathic intracranial hypertension: a real‐world propensity score‐matched study
Annals of Clinical and Translational Neurology, EarlyView.Abstract Objective Idiopathic intracranial hypertension (IIH) is a neurological disorder predominantly affecting young women with obesity, characterized by elevated intracranial pressure. While current treatments include weight loss counseling, medical therapies, and surgical interventions, their limitations necessitate exploring novel therapeutic ...
Ahmed Y. Azzam +13 more
wiley +1 more source